Dr. Donald Basile, born in 1970, holds a B.S. in Economics from Cornell University. He was the CEO of CompoSecure, Inc., a company that went public through a SPAC merger. His time as CEO was marked by substantial insider trading...

Dr. Donald Basile, born in 1970, holds a B.S. in Economics from Cornell University. He was the CEO of CompoSecure, Inc., a company that went public through a SPAC merger. His time as CEO was marked by substantial insider trading activity, with his stock holdings peaking at around $48.53 million in December 2021, before fluctuating significantly over the following months, reflecting a keen market awareness. Dr. Basile resigned from his board position at CompoSecure in September 2022 but remains an influential figure in tech and finance, having previously led companies like FusionIO and Violin Memory. His background is in electrical engineering, having earned his Ph.D. from Stanford, which gives him a strong technical edge in understanding complex business landscapes. Despite receiving no reported compensation for his CEO role in 2021, his decisions and strategies have significantly impacted the stock's movements, showcasing his involvement in high-stakes financial environments. Dr. Basile's career reflects a commitment to innovation, bridging technology and business.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other CompoSecure, Inc. CEOs

C

Dr. Donald Basile

Ex-CEO of CompoSecure, Inc.

Education

B.S. in Economics from Cornell University

Field of Expertise

Business & Management

Sector of Economy

Industrials

Born

January 1, 1970 - 55 years ago

CEO of CompoSecure, Inc. for

0 years 8 months (Dec 2021 - Sep 2022)

Previous Experience

CEO of Brightstar Corp., CEO of VeriFone Systems, Inc., CEO of Citigroup Inc.'s Enterprise Payments business

Rivals

Competitors/colleagues of Dr. Donald Basile

Holdings

See how much did Dr. Donald Basile make over time.

Dr. Donald Basile has had significant fluctuation in his stock holdings since becoming CEO of CompoSecure, peaking at approximately $48.53 million in December 2021. Over time, this amount fell to around $4.21 million by February 2023. Each month showed a...

Dr. Donald Basile has had significant fluctuation in his stock holdings since becoming CEO of CompoSecure, peaking at approximately $48.53 million in December 2021. Over time, this amount fell to around $4.21 million by February 2023. Each month showed a steady decline, with his holdings shrinking from $44.43 million in January 2022 to $2.19 million in June 2023. This sharp decrease illustrates the volatility and dynamic nature of stock valuations within the tech sector. Dr. Basile’s active trading choices highlight his strategic approaches to managing his wealth, reflecting broader market sentiments and potential insider perspectives on the company’s performance.

Total Stock Sold

$30.86M

CMPO

$30.86M

5,473,667 CMPO shares

What if they kept their stock?

If Dr. Donald Basile didn't sell their stock, today they would have:
Extra CMPO5,473,667 shares worth $52.33M.
This is 69.58% and $21.47M more than what they got when they sold the stock.

Insider Trading

See recent insider trades of Dr. Donald Basile.

CMPO

$4.79M

CMPO at $6.25/share

Feb 10, 2023

Sale

CMPO

$1.51M

CMPO at $6.19/share

Feb 7, 2023

Sale

CMPO

$1.16M

CMPO at $6.23/share

Feb 2, 2023

Sale

CMPO

$627.78K

CMPO at $6.28/share

Jan 27, 2023

Sale

CMPO

$1.66M

CMPO at $5.94/share

Jan 23, 2023

Sale

CMPO

$2.12M

CMPO at $5.48/share

Jan 18, 2023

Sale

CMPO

$6.05M

CMPO at $5.00/share

Jan 12, 2023

Sale

CMPO

$731.30K

CMPO at $4.93/share

Jan 9, 2023

Sale

CMPO

$6.37K

CMPO at $4.81/share

Dec 27, 2022

Sale

CMPO

$613.54K

CMPO at $4.94/share

Dec 15, 2022

Sale

Compensation History

See how much did Dr. Donald Basile make over time.

In 2021, Dr. Donald Basile's total compensation as CEO of CompoSecure was notably absent, as he received no salary, bonuses, or stock options. This unusual situation points to his equity stake in the company and investment strategy rather than traditional executive pay structures. The company emphasizes aligning executive compensation with performance, but specifics remained undisclosed for Dr. Basile. His lack of direct financial remuneration may suggest a personal investment approach with a long-term view on stock performance, reflecting confidence in the company's future direction. Dr. Basile's strategy demonstrates a focus on wealth accumulation through equity rather than immediate compensation, aligning his interests closely with the company's success.

Year

2021

Total Compensation

$0.00

Salary

$0.00

Board Justification

The company aims to align executive compensation with performance and market standards, but specific details for Dr. Basile were not provided in the proxy statement.

Bonus

$0.00

Board Justification

No bonus was reported for the year 2021.

Other

$0.00

Board Justification

No other compensation was reported for the year 2021.

Restricted Stock

$0.00(0 N/A)

Board Justification

No vested stock was reported for the year 2021.

Performance Metrics

No performance metrics were reported for Dr. Basile's compensation in 2021.

Other CompoSecure, Inc. CEOs

Here are other CEOs of CompoSecure, Inc.

Paul S. Galant

CEO of CompoSecure, Inc.

September 2022 - Present